Use of molecular targeted therapy for hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer in real-world clinical practice

CONCLUSIONS: Molecular targeted therapy (MTT) was mostly used in ≥ 3rd lines, and PFS of patients receiving 1st/2nd line and ≥ 3rd line treatments was similar; however, this study included heavily treated patients and a limited number of cases. Treatment options should take into consideration the maximal benefit to the patient based on the results of clinical trials.PMID:33867426 | DOI:10.1272/jnms.JNMS.2022_89-203
Source: Journal of Nippon Medical School - Category: Universities & Medical Training Authors: Source Type: research